Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Preferred Stock Liabilities (2016 - 2018)

Sutro Biopharma (STRO) has disclosed Preferred Stock Liabilities for 3 consecutive years, with $187.2 million as the latest value for Q3 2018.

  • Quarterly Preferred Stock Liabilities changed N/A to $187.2 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $187.2 million through Sep 2018, changed N/A year-over-year, with the annual reading at $102.5 million for FY2017, 0.0% changed from the prior year.
  • Preferred Stock Liabilities hit $187.2 million in Q3 2018 for Sutro Biopharma, up from $102.5 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $187.2 million in Q3 2018 to a low of $102.5 million in Q4 2016.
  • Historically, Preferred Stock Liabilities has averaged $130.8 million across 3 years, with a median of $102.5 million in 2016.
  • Biggest YoY gain for Preferred Stock Liabilities was 0.0% in 2017; the steepest drop was 0.0% in 2017.
  • Year by year, Preferred Stock Liabilities stood at $102.5 million in 2016, then changed by 0.0% to $102.5 million in 2017, then soared by 82.67% to $187.2 million in 2018.
  • Business Quant data shows Preferred Stock Liabilities for STRO at $187.2 million in Q3 2018, $102.5 million in Q4 2017, and $102.5 million in Q4 2016.